Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...

It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...

Systemic manifestations of gnathostomiasis can affect the skin, brain, gastrointestinal tract and respiratory system, while ocular involvement is rare. 5 Intraocular gnathostomiasis, though uncommon, ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).